Scott A Monsma

Title: The Innovations of Scott A. Monsma

Introduction

Scott A. Monsma is an accomplished inventor based in Madison, WI (US). He holds a total of 3 patents that contribute significantly to the field of gene therapy. His work focuses on the development of baculoviruses that can efficiently deliver genes to mammalian cells.

Latest Patents

Monsma's latest patents include innovative technologies such as GP64-null baculoviruses pseudotyped with heterologous envelope proteins for gene therapy. This pseudotyped baculovirus features a deletion, inactivation, or reduction from regulation of a baculovirus envelope protein gene. It is engineered to express an envelope protein from another virus or cell, facilitating entry into non-host cells. These baculoviruses can deliver genes effectively, allowing for expression from either the baculovirus genome or integration into the mammalian cell genome. This technology enables the expression of proteins without the need to remove contaminating baculovirus particles or envelope proteins.

Career Highlights

Throughout his career, Monsma has worked with notable organizations such as the Boyce Thompson Institute for Plant Research and Novagen, Inc. His contributions to these institutions have furthered research in gene therapy and biotechnology.

Collaborations

Monsma has collaborated with esteemed colleagues, including Gary W. Blissard and Jodie T. Mangor. These partnerships have enhanced the development of his innovative technologies.

Conclusion

Scott A. Monsma's work in the field of gene therapy through the development of baculoviruses showcases his significant contributions to biotechnology. His patents reflect a commitment to advancing medical science and improving gene delivery methods.